KORRO BIO, INC.
NASDAQ: KRRO (Korro Bio, Inc.)
Kemas kini terakhir: 14 jam lalu10.02
-1.78 (-15.08%)
| Penutupan Terdahulu | 11.80 |
| Jumlah Dagangan | 762,905 |
| Harga / Jualan (P/S) | 50.54 |
| Harga / Buku (P/B) | 1.43 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -981.18% |
| EPS Cair (TTM) | -9.42 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.52% |
| Nisbah Semasa (MRQ) | 9.41 |
| Aliran Tunai Operasi (OCF TTM) | -62.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -61.34 M |
| Pulangan Atas Aset (ROA TTM) | -29.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Korro Bio, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.25 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.18% |
| % Dimiliki oleh Institusi | 104.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lynx1 Capital Management Lp | 30 Jun 2026 | 1,538,296 |
| Atlas Venture Life Science Advisors, Llc | 30 Jun 2026 | 962,884 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DOLAN OLIVER | - | 13.42 | -7,358 | -99,405 |
| FORMELA JEAN FRANCOIS | - | 13.85 | -48,690 | -675,103 |
| Jumlah Keseluruhan Kuantiti Bersih | -56,048 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -774,508 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 13.59 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | Pengarah | 14 Sep 2026 | Jual automatik (-) | 38,490 | 13.88 | 534,241 |
| DOLAN OLIVER | Pegawai | 11 Sep 2026 | Jual automatik (-) | 5 | 13.81 | 69 |
| FORMELA JEAN FRANCOIS | Pengarah | 11 Sep 2026 | Jual automatik (-) | 10,200 | 13.81 | 140,862 |
| DOLAN OLIVER | Pegawai | 09 Sep 2026 | Jual automatik (-) | 6 | 12.93 | 78 |
| DOLAN OLIVER | Pegawai | 08 Sep 2026 | Jual automatik (-) | 7,347 | 13.51 | 99,258 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |